Lyell Immunopharma, Inc. — Director's Dealing 2022

Dec 19, 2022

SEC Form 4 — Statement of Changes in Beneficial Ownership

Issuer: Lyell Immunopharma, Inc. (LYEL)
CIK: 0001806952
Period of Report: 2022-12-15

Reporting Person: Seely Lynn (Director, President and CEO)

Derivative Transactions

Date	Security	Exercise Price	Code	Shares	A/D	Expiration	Underlying	Ownership
2022-12-15	Option (right to buy)	$3.28	A	7500000	Acquired	2032-12-14	Common Stock (7500000)	Direct

Footnotes

F1: Twenty-five (25) percent of the shares subject to the option shall vest on December 15, 2023 and 1/48th of the shares subject to the option shall vest in equal monthly installments thereafter until all shares are vested, subject to the reporting person remaining an employee of the Issuer on each applicable vesting date.